

Dr Sherin Al-Safadi Appointed as Vice President Medical and Corporate Affairs

Sydney, Australia – 24 July 2023 – Radiopharm Theranostics (ASX:RAD, Company), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Sherin Al-Safadi to the position of Vice President Medical and Corporate Affairs. Sherin is an accomplished industry leader with many years of experience in pharmaceuticals and biotech.

Most recently, Dr Al-Safadi held the role of Vice-President – Medical Affairs at POINT Biopharma, where she assembled and headed up a medical affairs division and led the strategic and tactical planning for Phase III support and launch preparation of radiopharmaceuticals. She also provided strategic input and leadership for business development and licensing opportunities.

She currently serves as Co-Founder and President at Foundation Amal (Canada-USA), overseeing an executive leadership team of 12 directors and members. During her time there, she led the successful 2021 cross-border expansion into the USA and spearheaded the development of a successful branding and communication strategy.

Previously, she held leadership roles at multinational pharmaceutical and biotechnology companies including Bayer, where she served as Director of Global Medical Affairs Oncology. In this role, she led franchise-specific strategic guidance and KPIs for global Med Affairs teams launch excellence, including the transition to hybrid digital engagement.

Dr Al-Safadi holds a PhD in Neurobiology from Concordia University, an MBA in Entrepreneurship & Management from the John Molson School of Business, and a MSc in Pharmacology (oncology drug development) from McGill University.

"We are thrilled to have Sherin join our team at Radiopharm Theranostics," said Riccardo Canevari, Managing Director and CEO of Radiopharm. "Her expertise and leadership skills will be invaluable as we continue to grow and develop our pipeline of radiopharmaceutical products. In particular, with F18- Pivalate entering late-stage development, the Medical Affairs function becomes a critical success factor. "

Dr Al-Safadi commence in the role today.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

**ASX ANNOUNCEMENT
24 JULY 2023**



Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>